Improvement of Sepsis by Hepatocyte Growth Factor, an Anti-Inflammatory Regulator: Emerging Insights and Therapeutic Potential
Figure 2
Therapeutic effects of recombinant HGF on MOF induced by LPS in mice. (a) Inhibitory effect of HGF treatment on cytokine storm. LPS-induced increases in plasma IL-1β, IL-6, and IL-18 levels were inhibited by HGF treatment. There are significant differences between saline- and HGF-treated septic groups (24 hours after challenge, ANOVA test). (b) Attenuations of histological lesions, such as hepatic degeneration, lung edema, and renal congestion by HGF in LPS-treated mice. (c) Prevention of hepatic, pulmonary and renal dysfunctions by HGF in septic mice. ALT: alanine aminotransferase. BUN: blood urea nitrogen. There are significant differences between saline- and HGF-treated septic groups (24 hours after challenge, ANOVA test). (d) Improved survival rate within 4 days after HGF treatment ( per group), with a significant difference (96 hours, Kaplan-Meier test). Overall, recombinant HGF was shown to prohibit septic MOF in a mouse model of sepsis [28, 29].
